Wed, Apr 15 · 8:30

Let RWE illuminate a better path for all stakeholders
Let’s address the elephant in the room: RWE is part of every plan, yet a huge cloud of uncertainty hangs over it.

Why? Because while we see RWE powering positive change, our colleagues don’t understand our worth.

It’s true that RWE is the best tool to succeed in the transition to a value-based model, but if we’re unable to demonstrate how RWE works, we won’t get far. ICER, MIT NEWDIGS, Patient Groups, Transcelerate and several senior industry leaders will congregate at eyeforpharma Philadelphia to determine how RWE can advance critical functional objectives. You will see how RWE can raise the bar on personalized customer engagement, improve scientific education, advance R&D and – perhaps most importantly – prove its value to patients, payers and providers.

4 essential RWE & Data Science themes for 2020:

Create cross-functional RWE champions:
Convince internal stakeholders with compelling examples of how evidence can rapidly advance functional strategy

Supercharge AI with RWE:
Break boundaries across both patient, payer, provider engagement AND clinical research with an AI strategy that is powered by RWE

Collaborate With Your Competition to scale patient registries:
Solve the RWE data bottleneck by letting patient groups lead to create willing coalitions built on trust

Demonstrate value through evidence:
Help payers and providers gain value from RWE and create the infrastructure to put insights into action across the lifecycle

Website https://go.evvnt.com/547462-2?pid=5731

Brochure https://go.evvnt.com/547462-3?pid=5731 

Prices:

Pharma Silver Pass USD 1699.00

Solution Provider Silver Pass USD 2199.00

Speakers: Chris Leibman SVP, Value and Access Biogen, Sarah Emond EVP and COO ICER, Anne Heatherington SVP, Head of Data Sciences Institute Takeda, Caren Heller CSO Crohns Colitis foundation, Mark Trusheim Strategic Director MIT NEWDIGS, Thomas Abbott Head, Real World Evidence Astellas, Eric Widdbrodt Renal Evidence Strategy Lead AstraZeneca